Table II.
Association between immunohistochemical MZB1 expression and clinicopathological characteristics in 114 patients with breast cancer.
| Clinicopathological parameter | MZB1-positive group (n=64) | MZB1-negative group (n=50) | P-value |
|---|---|---|---|
| Age | 0.009a | ||
| ≤60 years | 46 | 24 | |
| >60 years | 18 | 26 | |
| Histology | 0.477 | ||
| Ductal carcinoma in situ | 2 | 4 | |
| Invasive ductal carcinoma | 56 | 43 | |
| Invasive lobular carcinoma | 2 | 2 | |
| Other | 4 | 1 | |
| UICC T factor | 0.181 | ||
| Tis/T1 | 24 | 25 | |
| T2/T3/T4 | 40 | 25 | |
| Node status | 0.706 | ||
| Negative | 31 | 26 | |
| Positive | 33 | 24 | |
| UICC pathological stage | 0.326 | ||
| 0/I/II | 49 | 42 | |
| III | 15 | 8 | |
| ER status | 0.003a | ||
| Positive | 55 | 31 | |
| Negative | 9 | 19 | |
| PgR status | 0.003a | ||
| Positive | 50 | 26 | |
| Negative | 14 | 24 | |
| HER2 status | 0.878 | ||
| Positive | 13 | 12 | |
| Negative | 43 | 37 | |
| Unknown | 8 | 1 | |
| Triple-negative | 0.023a | ||
| Yes | 3 | 9 | |
| No | 60 | 41 | |
| Unknown | 1 | 0 | |
| Adjuvant therapy | 0.175 | ||
| Endocrine therapy alone | 27 | 18 | |
| Chemotherapy alone | 9 | 11 | |
| Endocrine and chemotherapy | 24 | 13 | |
| None | 4 | 8 |
P-values were determined using a χ2 test.
a
P<0.05. ER, estrogen receptor; HER2, human epidermal growth factor 2; MZB1, marginal zone B and B1 cell-specific protein; PgR, progesterone receptor; UICC, Union for International Cancer Control.